Edward Andrle
Known title: DirectorCIK: 0001656026
Associated companies
Transaction History
| NMTC | ▲ Buy | Grant | 41,929 | $0 | 4/3/2026 | View on chart |
| NMTC | ▲ Buy | Grant | 27,778 | $0 | 2/14/2025 | View on chart |
| NMTC | ▲ Buy | Grant | 20,576 | $0 | 3/16/2023 | View on chart |
| NMTC | ▲ Buy | Grant | 29,240 | $0 | 5/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NeuroOne Reports Strong Q4 Sales, New $4.5M Order
NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.
NeuroOne Reports Strong Q4 Sales, New $4.5M Order. NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.